Trial NCT04497948

View at ClinicalTrials.gov 
Org. Study IDs: D822FC00005

Last trial update was posted on 2021-11-17

MeSH Interventions

Acalabrutinib

MeSH Conditions

COVID-19

Other Conditions


Stopping Reasons

Data from the CALAVI Phase II trials for Acalabrutinib in patients hospitalized with COVID-19 did not meet their primary efficacy endpoints. Based on this higher management made the decision to prematurely terminate the D822FC00005 PK study.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID